(Rhabdomyo)sarcoma

Soft tissue sarcomas represent a rare and diverse group of mesenchymal tumors, accounting for approximately 8% of all childhood cancers. Over 50% of these cases are diagnosed as rhabdomyosarcoma (RMS), a tumor orginating from developing skeletal muscle. Despite optimal surgical, radiation, and chemotherapy treatments, survival for high-risk RMS remains below 20%. 

This underscores the urgent need for innovative therapeutic strategies to improve outcomes in high-risk RMS patients.

Therefore, we aim to advance targeted therapy options for pediatric (rhabdomyo)sarcoma.